Lipoprotein lipase (LPL) mRNA expression predicts a more aggressive phenotype and disease evolution in chronic lymphocytic leukemia, although its exact functional role remains unclear.
What is the prognostic and biological relevance of lipoprotein lipase in chronic lymphocytic leukemia?
LPL expression serves as a prognostic marker for aggressive disease evolution in chronic lymphocytic leukemia, though its exact biological function in this context remains unclear.
Chronic lymphocytic leukemia (CLL) is a clinically heterogeneous disease characterized by the accumulation of a clonal population of B cells in peripheral blood, bone marrow, and lymphoid organs. More than 10 years ago, lipoprotein lipase (LPL) mRNA was identified as being strongly expressed in patients experiencing a more aggressive phenotype, while CLL patients with an indolent disease course lack expression of this marker. Since then, several reports confirmed the capability of LPL to predict CLL disease evolution at the moment of diagnosis. In contrast, data on the functional implications of LPL in CLL are scarce. LPL exerts a central role in overall lipid metabolism and transport, but plays additional, non-catalytic roles as well. Which of those is more important in the pathogenesis of CLL remains largely unclear. Here, we review the current knowledge on the prognostic and biological relevance of LPL in CLL.
Rombout et al. (Tue,) conducted a review in Chronic lymphocytic leukemia (CLL). Lipoprotein lipase (LPL) was evaluated. Lipoprotein lipase (LPL) mRNA expression predicts a more aggressive phenotype and disease evolution in chronic lymphocytic leukemia, although its exact functional role remains unclear.